The present and previous studies demonstrating the efficacy of M109S in mouse retinal disease models suggest that M109S has a potential to become the basis of future orally available therapeutics protecting essential cells from unwanted BAX-mediated cell death in various diseases. Here, BAX is linked to Abnormal retinal morphology.